When I first started seeing the headlines about GLP-1 medications for weight loss, I was skeptical
The prior authorization process requires documentation of comorbid medical conditions that can be improved or eliminated by taking GLP-1 medications
Your body does not work that way, and twice the units means twice the medication, which means dramatically increased side effect risk
In contrast, the newer incretin-based therapies, such as GLP-1 receptor agonist and dual GLP-1/GIP receptor agonists, show lower non-response rates
The recommended baseline panel for menopausal women considering weight loss peptides includes: fasting glucose and HbA1c (metabolic baseline), fasting insulin (insulin resistance assessment), lipid panel including triglycerides (cardiovascular risk), complete metabolic panel (liver and kidney function), IGF-1 (baseline for GH secretagogue monitoring), thyroid panel including TSH and free T4, estradiol and FSH (menopausal status confirmation), and DEXA scan if available (body composition baseline)